patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Reply New Message

Prev Message Back To Forum Threaded View Next Message

bankerson

Rank: Treasurer [?]

Points: 22820 [?]

Votes: 138 Score: 2.9 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

letter to shareholders !

posted on Oct 09, 2012 08:20AM

Pluristem Issues Letter to Shareholders Highlighting Significant Achievements on Several Fronts

ARTICLE

Increasing Cash Position to About $70 Million, Targeting Future Clinical Trials in Bone Marrow Transplant Failure Indications, Progress in Clinical Trials, New Regulatory Approvals & New Manufacturing Facilities to Service Markets

HAIFA, Israel, Oct. 9, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that the Company has issued a letter to shareholders that provides an overview of the numerous milestones recently achieved by the company. The letter can be found on the company's website. Highlights include:

To read Pluristem's Letter to Shareholders in full, please visit:

http://www.pluristem.com/index.php?option=com_content&view=article&id=25 0&catid=4&Itemid=104

2 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply